<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156479">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014792</url>
  </required_header>
  <id_info>
    <org_study_id>DNS9195677</org_study_id>
    <nct_id>NCT02014792</nct_id>
  </id_info>
  <brief_title>Heart Rate Variability &amp; Fatty Acid Status: Haemodialysis Patients</brief_title>
  <official_title>Heart Rate Variability and Omega-3 Fatty Acid Status in Haemodialysis Patients: an Observational Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <authority>UK: National Research Ethics Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest that dietary omega-3 fatty acids influence the extent to which the time
      interval between each heart beat varies (heart rate variability; HRV). Low HRV is associated
      with increased risk of sudden cardiac death (SCD). The purpose of this research is to
      investigate the relationship between 24 hour parameters of HRV and blood omega-3 fatty acid
      levels in patients who have recently commenced haemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Erythrocyte eicsapentaenoic acid (EPA) + docosahexaenoic acid (DHA) content (% weight of total fatty acids)</measure>
    <time_frame>6-10 wk after commencing haemodialysis treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary independent variable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour heart rate variability (Triangular index and SDNN)</measure>
    <time_frame>6-10 weeks after commencing haemodialysis treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary dependent variables. Triangular index and SDNN are indicators of overall variability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 h heart rate variability - longer phase parameters</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters of longer phase HRV: LF, VLF and SDANN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 h heart rate variability - short-phase parameters</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
    <description>RMSSD, pNN50, HF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal heart rate variability - all parameters</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
    <description>SDNN, Triangular index, LF, HF, VLF, SDANN, RMSSD, pNN50 calculating during nocturnal sleep-time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma EPA+DHA content (% weight of total fatty acids)</measure>
    <time_frame>6-10 weeks after commencing haemodialysis6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Complications of haemodialysis in first 6 weeks of starting treatment</measure>
    <time_frame>0-6 weeks after commencing haemodialysis</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of problems with dialysis access, inadequate urea reduction ratio, amount of excess oedematous fluid removed, serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Background dietary intakes</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
    <description>Food frequency questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>History of sleep apnoea</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
    <description>Epworth Sleepiness scale and Berlin questionnaire, plus relevant medical history</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>12 month average blood pressure</measure>
    <time_frame>12 months prior to commencing haemodialysis treatment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipids</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Serum electrolytes</measure>
    <time_frame>6-10 weeks after commencing haemodialysis</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sodium, potassium, calcium, phosphate</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Chronic kidney disease, stage 5</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending King's College Hospital and Guy's and St Thomas' Hospitals who have
        recently commenced haemodialysis treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD stage 5 commencing haemodialysis,

          -  male or female,

          -  aged 40-80 y,

          -  written informed consent

        Exclusion Criteria:

          -  history of chronic liver disease or neuropathy, infection or antibiotics within the
             last month.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iain Macdougall, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen MacLaughlin, PhD</last_name>
    <phone>+44 (0)20 32996250</phone>
    <email>helen.maclaughlin@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen MacLaughlin, PhD</last_name>
      <email>helen.maclaughlin@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Helen MacLaughlin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iain Macdougall, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Hall, PhD</last_name>
      <phone>(0)20 78484197</phone>
      <email>wendy.hall@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ana Pinto</last_name>
      <email>ana_margarida.pinto@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ana Pinto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Sanders, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Wendy Hall</investigator_full_name>
    <investigator_title>Lecturer in Nutritional Sciences</investigator_title>
  </responsible_party>
  <keyword>Haemodialysis</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>n-3 PUFA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
